论文部分内容阅读
目的观察阿奇霉素治疗儿童支原体肺炎的临床疗效及安全性。方法选取医院收治的支原体肺炎患儿56例为研究对象,随机分为对照组和观察组,每组28例。2组患儿均给予镇咳、化痰、退热及平喘等常规治疗,对照组在常规治疗基础上给予红霉素治疗,观察组在常规治疗基础上给予阿奇霉素治疗,观察患儿临床疗效、临床体征及住院时间。结果观察组总有效率为92.86%,高于对照组的71.43%(P<0.05);观察组各项临床体征持续时间及住院时间均显著短于对照组(P<0.01)。结论阿奇霉素对于支原体感染具有较强的抗菌活性,应用于儿童支原体肺炎的治疗中具有疗效确切、起效时间短以及用药安全的明显优越性,值得临床推广应用。
Objective To observe the clinical efficacy and safety of azithromycin in children with mycoplasma pneumonia. Methods Fifty-six children with mycoplasmal pneumonia admitted to hospital were selected as study subjects and randomly divided into control group and observation group with 28 cases in each group. The two groups of children were given antitussive, phlegm, fever and asthma and other conventional treatment, the control group on the basis of conventional treatment with erythromycin, the observation group on the basis of conventional treatment given azithromycin to observe the clinical efficacy of children , Clinical signs and hospitalization time. Results The total effective rate in the observation group was 92.86%, which was higher than 71.43% in the control group (P <0.05). The duration of the clinical signs and hospital stay in the observation group were significantly shorter than those in the control group (P <0.01). Conclusion Azithromycin has strong antimicrobial activity against Mycoplasma infection. It has definite curative effect, short effective time and safe medication in the treatment of children with Mycoplasma pneumonia. It is worthy of clinical application.